EXCLUSIVE: Drug companies choosing not to sell life-saving and life-extending medicines in Canada
When Ruchi Ambike found out that Novartis got Health Canada approval for Vanrafia she was ecstatic. The drug can possibly slow down the progression of her Immunoglobulin gA nephropathy, (IgAN) and ultimately, end-stage kidney disease. “It’s exciting because we have no IgAN drugs in Canada,” she says from her Mississauga home. IgAN is a rare […]
We haven't written up this one. CityNews has the full story — the link below goes straight to it.
